OncoMatch/Clinical Trials/NCT07093554
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
Is NCT07093554 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Talquetamab and Ciltacabtagene Autoleucel for relapse multiple myeloma.
Treatment: Talquetamab · Ciltacabtagene Autoleucel — This is a single-arm, open-label, phase 1b study evaluating the safety and feasibility of using talquetamab as bridging therapy prior to cilta-cel in patients with relapsed and refractory multiple myeloma (RRMM).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
Patient had at least one prior line of therapy (PLOT), including a proteasome inhibitor (PI), an anti-CD38 antibody, and an immunomodulatory drug (IMID).
Must have received: anti-CD38 antibody
Patient had at least one prior line of therapy (PLOT), including a proteasome inhibitor (PI), an anti-CD38 antibody, and an immunomodulatory drug (IMID).
Must have received: immunomodulatory drug
Patient had at least one prior line of therapy (PLOT), including a proteasome inhibitor (PI), an anti-CD38 antibody, and an immunomodulatory drug (IMID).
Cannot have received: adoptive T-cell therapy (CAR T-cell therapy)
Adoptive T-cell therapy (e.g., CAR T-cell therapy) at any time prior to enrollment.
Cannot have received: bispecific antibody
Bispecific antibody, investigational or approved, irrespective of its target, at any time prior to enrollment.
Cannot have received: talquetamab (talquetamab)
Use of talquetamab prior to enrollment.
Cannot have received: BCMA-targeted therapy
Any therapy targeting BCMA or GPRC5D, including but not limited to antibody-drug conjugates and/or monoclonal antibodies.
Cannot have received: GPRC5D-targeted therapy
Any therapy targeting BCMA or GPRC5D, including but not limited to antibody-drug conjugates and/or monoclonal antibodies.
Cannot have received: allogeneic stem cell transplant
Prior allogeneic stem cell transplant at any time.
Cannot have received: autologous stem cell transplant
Exception: within 2 months of date of enrollment
Autologous stem cell transplant within 2 months of date of enrollment.
Cannot have received: high-dose cytotoxic chemotherapy (DCEP, KD-PACE, D-PACE)
Exception: within 28 days of the enrollment date
High-dose cytotoxic chemotherapy (e.g., DCEP, KD-PACE, D-PACE) within 28 days of the enrollment date.
Cannot have received: cytotoxic chemotherapy (cyclophosphamide)
Exception: within 14 days of the enrollment date
Cytotoxic chemotherapy, such as cyclophosphamide, within 14 days of the enrollment date.
Cannot have received: proteasome inhibitor
Exception: within 7 days of the enrollment date
Treatment with a PI, IMID, anti-CD38 antibody, or venetoclax within 7 days of the enrollment date.
Cannot have received: immunomodulatory drug
Exception: within 7 days of the enrollment date
Treatment with a PI, IMID, anti-CD38 antibody, or venetoclax within 7 days of the enrollment date.
Cannot have received: anti-CD38 antibody
Exception: within 7 days of the enrollment date
Treatment with a PI, IMID, anti-CD38 antibody, or venetoclax within 7 days of the enrollment date.
Cannot have received: BCL2 inhibitor (venetoclax)
Exception: within 7 days of the enrollment date
Treatment with a PI, IMID, anti-CD38 antibody, or venetoclax within 7 days of the enrollment date.
Cannot have received: corticosteroid (dexamethasone)
Exception: cumulative dexamethasone dose of ≥ 100 mg within 14 days of the enrollment date
A cumulative dexamethasone dose of ≥ 100 mg within 14 days of the enrollment date.
Cannot have received: radiation therapy
Exception: within 7 days of the enrollment date
Radiation therapy within 7 days of the enrollment date.
Lab requirements
Blood counts
Hemoglobin ≥ 8.0 g/dL; Absolute Neutrophil Count ≥ 1,000/mcL; Absolute Lymphocyte Count ≥ 200/mcL; Platelets ≥ 25,000/mm^3 (transfusion and growth factor support within 72 hours allowed)
Kidney function
Creatinine Clearance ≥ 30 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
Liver function
Total Bilirubin < 2 mg/dL; AST/ALT < 5 times institutional upper limit
Cardiac function
No NYHA class III or IV CHF; no MI, unstable angina, stent, or CABG in last ≤ 6 months; ejection fraction > 40%; no severe non-ischemic cardiomyopathy
Adequate bone marrow function: Hemoglobin ≥ 8.0 g/dL; Absolute Neutrophil Count ≥ 1,000/mcL; Absolute Lymphocyte Count ≥ 200/mcL; Platelets ≥ 25,000/mm^3 (transfusion and growth factor support within 72 hours allowed). Adequate hepatic function: Total Bilirubin < 2 mg/dL; AST/ALT < 5 times institutional upper limit. Adequate renal function: Creatinine Clearance ≥ 30 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal. Cardiac: see exclusion criteria for details.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Froedtert & the Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07093554 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior adoptive T-cell therapy, bispecific antibody, talquetamab disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages